Shots:

• Novartis to acquire The Medicine Company in all-cash transaction for $85/share at a 24% 1-day premium- making fully diluted equity value as $7.7B and a total deal value as $9.7B. The transaction is expected to be closed in Q1’20  
• The acquisition will expand Novartis’ global footprints with the addition of Inclisiran in cardiovascular portfolio- thus enable Novartis to leverage its commercial capabilities globally
• The Medicine Company’s Inclisiran is first-in-class siRNA inhibitor targeting PCSK9- currently being evaluated in P-III (ORION-9- 10 and 11) studies for patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH)- demonstrating potent and durable LDL-C reduction with its expected regulatory submission in the US in Q4’19 and in the EU in Q1’20

Click here to­ read full press release/ article | Ref: Novartis  | Image: Chemistry World